Positive Phase II For Sanofi-Chasing Valneva/GSK C.Diff Vaccine
This article was originally published in Scrip
Valneva has reported positive topline Phase II data for its prophylactic vaccine candidate against Clostridium difficile infection. The product – which is partnered with GlaxoSmithKline – is the second in development behind Sanofi's prophylactic vaccine candidate, claims Valneva CEO Thomas Lingelbach. He also believes Valneva's product could offer advantages over Sanofi's product. Pfizer also has a prophylactic C. difficile vaccine candidate in Phase II development.